NEUROPAT FORTE CAPSULES

Indications

• Hypertension
• Benign prostatic hyperplasia
• Urinary retention related to prostate enlargement

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines in the paediatric population.

Adults: Refer to the BNF for specific dosing recommendations based on individual clinical scenarios.

Mechanism of action

Alpha acts by selectively blocking alpha-1 adrenergic receptors, which are responsible for mediating vasoconstriction in blood vessels. By inhibiting these receptors, alpha promotes vasodilation, leading to a decrease in peripheral vascular resistance and subsequently lowering blood pressure. Additionally, this action can help alleviate urinary symptoms associated with an enlarged prostate.

Pharmacodynamics

The pharmacodynamics of alpha involve its competitive antagonism at alpha-1 adrenergic receptors, resulting in decreased vasoconstriction and increased blood flow. This mechanism is beneficial in conditions characterized by high blood pressure and urinary retention due to prostatic enlargement. The onset of action typically occurs within hours, with peak effects observed within a few days of consistent dosing.

Pharmacokinetics

Alpha is absorbed well from the gastrointestinal tract, with peak plasma concentrations achieved within 1-3 hours post-administration. The drug undergoes hepatic metabolism, primarily via cytochrome P450 enzymes, resulting in active and inactive metabolites. The elimination half-life varies, but it generally is around 6-12 hours, allowing for once-daily dosing in many cases. Renal excretion is a significant route for its metabolites, necessitating caution in patients with renal impairment.

Interactions

• maois, irreversible + alpha blockers: Severe (increases effects)
• ribociclib + alpha blockers: Severe (increases exposure)
• cobicistat + alpha blockers: Moderate (increases exposure)
• idelalisib + alpha blockers: Moderate (increases exposure)
• dronedarone + alpha blockers: Unknown (increases exposure)
• antifungals, azoles + alpha blockers: Unknown (increases exposure)
• crizotinib + alpha blockers: Unknown (increases exposure)
• imatinib + alpha blockers: Unknown (increases exposure)
• letermovir + alpha blockers: Unknown (increases exposure)
• clarithromycin + alpha blockers: Unknown (increases exposure)

Indications

• Diabetic neuropathy
• Diabetic complications
• Nutritional supplementation in thiamine deficiency

Dosage

Children: Refer to the BNF for Children for appropriate dosing information.

Adults: The usual adult dosage is 300 mg to 600 mg per day, divided into 2 to 3 doses.

Mechanism of action

Benfotiamine is converted into thiamine in the body, where it serves as a cofactor for several enzymes involved in carbohydrate metabolism. It helps to reduce the formation of advanced glycation end-products (AGEs) and modulates pathways involved in diabetic complications, including the hexosamine pathway and the polyol pathway.

Pharmacodynamics

Benfotiamine enhances the activity of thiamine-dependent enzymes, which play critical roles in energy metabolism. This action may lead to improved glucose utilization and reduced oxidative stress, which is particularly beneficial in conditions such as diabetes mellitus. By inhibiting the accumulation of toxic metabolites associated with hyperglycemia, benfotiamine may help mitigate diabetic complications.

Pharmacokinetics

Benfotiamine is well-absorbed from the gastrointestinal tract due to its lipophilic nature. After absorption, it is metabolized to thiamine and its active metabolites. The elimination half-life and excretion pathways are not well established but are thought to involve renal excretion, similar to other thiamine metabolites.

Pregnancy

Benfotiamine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

There are no data on the excretion of benfotiamine in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a cool, dry place, protected from light.

Formulations

• {'form': 'Capsules', 'strength': '300 mg'}
• {'form': 'Tablets', 'strength': '150 mg'}

Indications

• Folate deficiency
• Megaloblastic anemia
• Prevention of neural tube defects in pregnancy
• Supplementation in patients on certain medications (e.g., methotrexate)

Dosage

Children: Refer to the BNF for Children for appropriate pa

Adults: Refer to specific guidelines or the BNF for appropriate adult dosing based on the indication.

Mechanism of action

Folate functions as a coenzyme in the conversion of homocysteine to methionine, a process that is vital for DNA synthesis and repair. It is involved in the one-carbon metabolism pathway, where it acts as a carrier of one-carbon units necessary for the synthesis of purines and thymidylate, thus supporting the production of nucleotides and DNA. This mechanism is particularly important in rapidly dividing cells.

Pharmacodynamics

Folate is critical for the formation of red blood cells and the proper functioning of the nervous system. It aids in the production of nucleic acids, which are essential for cell proliferation. Folate deficiency can lead to impaired DNA synthesis, resulting in megaloblastic anemia characterized by the presence of large, immature red blood cells in the bloodstream. Adequate folate levels are also associated with reduced risk of neural tube defects in developing fetuses.

Pharmacokinetics

Folate is absorbed in the proximal part of the small intestine, primarily in the jejunum, and is transported in the bloodstream bound to plasma proteins. It undergoes hepatic metabolism and is stored mainly in the liver. The elimination half-life varies, but dietary folate can be retained in the body for several weeks. Excess folate is excreted through the urine. The bioavailability of folate from food sources is lower compared to synthetic folic acid found in supplements.

Interactions

• folates+fluorouracil: Severe (increases risk of toxicity)
• folates+antiepileptics: Moderate (decreases concentration)
• folates+fosphenytoin: Moderate (decreases concentration)
• folates+phenobarbital: Moderate (decreases concentration)
• folates+phenytoin: Moderate (decreases concentration)
• folates+primidone: Moderate (decreases concentration)
• sulfasalazine+folates: Unknown (decreases absorption)

Pregnancy

Folate is essential for fetal development and is often recommended to prevent neural tube defects.

Breast-feeding

Folate is generally safe during breastfeeding, as it is important for both maternal and infant health.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Tablets
• Injection

Indications

• Polycystic ovary syndrome (PCOS)
• Generalized anxiety disorder
• Depression
• Obsessive-compulsive disorder
• Insulin resistance

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines for paediatric patients.

Adults: Refer to the BNF for specific dosing recommendations, as doses may vary based on the condition being treated.

Mechanism of action

Inositol functions primarily as a precursor for the synthesis of phosphoinositides, which are key components of cell membranes. These phosphoinositides are involved in various intracellular signaling pathways, particularly those mediated by G-protein coupled receptors. Inositol also influences the action of neurotransmitters such as serotonin and has been shown to enhance insulin sensitivity and glucose metabolism.

Pharmacodynamics

Inositol has been observed to have mood-stabilizing effects and may improve insulin sensitivity. Its role in cell signaling impacts various physiological processes, including cellular communication and metabolic regulation. The therapeutic effects of inositol in psychiatric conditions may be attributed to its ability to modulate neurotransmitter systems, particularly involving serotonin and dopamine.

Pharmacokinetics

Inositol is well-absorbed from the gastrointestinal tract, with peak plasma levels occurring within 1 to 2 hours after ingestion. It is distributed throughout the body and can cross the blood-brain barrier. Inositol is predominantly excreted in the urine, with a half-life that varies based on dosage and individual metabolism. Metabolism occurs primarily through dephosphorylation to form various inositol phosphates.

Pregnancy

Inositol is generally considered safe during pregnancy but should be used under medical supervision.

Breast-feeding

Inositol is likely safe during breastfeeding, but consult a healthcare provider for specific recommendations.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Powder
• Capsules

Indications

• Primary hyperlipidemia
• Mixed dyslipidemia
• Familial hypercholesterolemia
• Prevention of cardiovascular disease

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing recommendations based on the condition being treated and patient factors.

Mechanism of action

Lipic functions by inhibiting the enzyme HMG-CoA reductase, which is a key regulatory enzyme in the mevalonate pathway of cholesterol biosynthesis. By blocking this enzyme, Lipic decreases the production of cholesterol in the liver, leading to an upregulation of LDL receptors on hepatocyte surfaces, thus increasing the clearance of LDL cholesterol from the bloodstream.

Pharmacodynamics

The pharmacodynamic effects of Lipic include a significant reduction in total cholesterol, LDL cholesterol, and triglycerides, while also potentially raising HDL cholesterol levels. This alteration in lipid profiles contributes to a reduced risk of cardiovascular events, such as heart attacks and strokes, particularly in patients with established cardiovascular disease or those at high risk.

Pharmacokinetics

Lipic is typically absorbed rapidly following oral administration, with peak plasma concentrations occurring within 1 to 4 hours. It is highly protein-bound, primarily to albumin, and undergoes extensive first-pass metabolism in the liver. The elimination half-life varies depending on the specific formulation but is generally within the range of 1 to 3 hours. Lipic is primarily excreted in the bile, with a small fraction eliminated via the kidneys. Its pharmacokinetics may be influenced by factors such as age, liver function, and concurrent medications.

Contra-indications

• Hypersensitivity to lipic or any of its components
• Active liver disease or unexplained persistent elevations of hepatic transaminases
• Pregnancy and breastfeeding
• Severe renal impairment
• Myopathy or history of statin-related myopathy

Adverse effects

• Muscle pain or weakness (myopathy)
• Liver enzyme abnormalities
• Gastrointestinal disturbances (e.g., nausea, diarrhea)
• Increased blood sugar levels
• Rhabdomyolysis (rare)
• Allergic reactions (e.g., rash, itching)

Interactions

• Increased risk of myopathy and rhabdomyolysis with concomitant use of other lipid-lowering agents
• Potential interactions with certain antibiotics (e.g., erythromycin) and antifungal agents (e.g., ketoconazole)
• Caution with drugs that inhibit CYP3A4, leading to increased plasma concentrations of lipic
• May interact with anticoagulants, requiring monitoring of INR

Precautions

• Monitor liver function tests before and during therapy
• Assess for history of muscle disorders
• Use with caution in patients with a history of alcohol abuse
• Consider alternative therapies in patients with diabetes or at risk for diabetes

Pregnancy

Use is contraindicated during pregnancy due to potential harm to the fetus.

Breast-feeding

Use is contraindicated while breastfeeding as it may affect the nursing infant.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets
• Capsules
• Extended-release formulations

Indications

• Vitamin B12 deficiency
• Megaloblastic anemia
• Peripheral neuropathy
• Neuropathic pain
• Multiple sclerosis

Dosage

Children: For paediatric patients, refer to the BNF for Children for appropriate dosing guidelines.

Adults: The typical adult dosage for methylcobalamin is 500 micrograms to 1,000 micrograms administered intramuscularly or subcutaneously, usually once daily for the initial treatment, followed by maintenance doses as needed.

Mechanism of action

Methylcobalamin serves as a cofactor for the enzyme methionine synthase, which catalyzes the conversion of homocysteine to methionine. This reaction is crucial in the synthesis of S-adenosylmethionine (SAMe), an important methyl donor in numerous methylation reactions within the body. Methylcobalamin also plays a role in myelin formation and the maintenance of nerve cells.

Pharmacodynamics

Methylcobalamin exhibits neuroprotective effects, promoting nerve regeneration and repair in peripheral neuropathy. It is believed to enhance nerve conduction and improve neurological function. The physiological effects are primarily attributed to its role in methylation processes and the synthesis of neurotransmitters.

Pharmacokinetics

Methylcobalamin is water-soluble and is absorbed in the intestine. The bioavailability can be affected by gastrointestinal health, and intrinsic factor is not required for its absorption. It is distributed throughout the body, with high concentrations in the liver, kidneys, and brain. The elimination half-life of methylcobalamin is approximately 6 hours, and it is excreted primarily in the urine.

Adverse effects

• Nausea
• Diarrhea
• Headache
• Dizziness
• Anxiety
• Rash
• Pruritus

Precautions

• Monitor patients with Leber's disease due to potential optic nerve damage.
• Caution in patients with allergies to cobalt or vitamin B12.
• Use with caution in patients with renal impairment.

Pregnancy

Methylcobalamin is classified as a category A drug. It is generally considered safe during pregnancy, but consultation with a healthcare provider is recommended.

Breast-feeding

Methylcobalamin is excreted in breast milk. It is generally considered safe during breastfeeding, but consultation with a healthcare provider is recommended.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Tablets
• Injections
• Sublingual tablets
• Oral solutions

Indications

• Vitamin B6 deficiency
• Anemia due to pyridoxine deficiency
• Neurological disorders (e.g., peripheral neuropathy)
• Certain metabolic disorders (e.g., homocystinuria)
• Dermatological conditions (e.g., seborrheic dermatitis)

Dosage

Children: Refer to the BNF

Adults: Refer to clinical guidelines for specific dosing recommendations, as doses may vary based on indication and individual patient needs.

Mechanism of action

Pyroxidine is converted into its active form, pyridoxal phosphate (PLP), which functions as a coenzyme in a variety of enzymatic reactions. It is involved in the metabolism of amino acids, carbohydrates, and lipids, and is crucial for the synthesis of neurotransmitters such as serotonin, dopamine, and gamma-aminobutyric acid (GABA). PLP contributes to the production of hemoglobin and the modulation of immune function.

Pharmacodynamics

Pyridoxine exhibits a range of pharmacological effects, primarily through its role as a cofactor in enzymatic reactions. It facilitates transamination, decarboxylation, and racemization reactions, which are central to amino acid metabolism. Additionally, it influences the synthesis of neurotransmitters, impacting mood and neurological function. Its role in hemoglobin synthesis helps prevent anemia, while its involvement in immune function supports overall health.

Pharmacokinetics

Pyridoxine is readily absorbed from the gastrointestinal tract after oral administration. It is widely distributed in body tissues, and its metabolism primarily occurs in the liver, where it is converted to its active form, pyridoxal phosphate. The elimination of pyridoxine and its metabolites occurs via renal excretion. The half-life of pyridoxine is approximately 15 to 20 days, depending on the individual's nutritional status and renal function.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal cramps
• Peripheral neuropathy (with high doses)
• Photosensitivity
• Hypersensitivity reactions

Interactions

• May interfere with the effectiveness of certain anticonvulsants
• High doses may reduce the effectiveness of levodopa
• May interact with isoniazid and penicillamine, which can induce pyridoxine deficiency

Precautions

• Use caution in patients with renal impairment
• Monitor for signs of neuropathy with prolonged high-dose therapy
• Consider dietary intake of vitamin B6 when prescribing

Pregnancy

Pyridoxine is generally considered safe during pregnancy and is often used to treat nausea and vomiting in pregnant women.

Breast-feeding

Pyridoxine is excreted in breast milk, but is typically safe for breastfeeding mothers.

Storage

Store in a cool, dry place, protected from light.

Formulations

• Tablets
• Injectable solution
• Oral suspension